1. Less invasive ventricular reconstruction for ischaemic heart failure
- Author
-
Patrick Klein, Andrew S. Wechsler, Tobias Schmidt, Lon Annest, Ivo Skalsky, Horst Sievert, Sebastian Kelle, Petr Neuzil, Theresa McDonagh, Stefan D. Anker, Mauro Bifi, Christian Frerker, and Anthony N. DeMaria
- Subjects
Male ,medicine.medical_specialty ,Beating heart ,Heart Ventricles ,Less invasive ,Myocardial Ischemia ,030204 cardiovascular system & hematology ,Nyha class ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,medicine ,Humans ,Myocardial infarction ,Prospective Studies ,Cardiac Surgical Procedures ,Heart Failure ,Ejection fraction ,Ventricular Remodeling ,business.industry ,Stroke Volume ,Equipment Design ,Middle Aged ,medicine.disease ,Treatment Outcome ,Heart failure ,Etiology ,Cardiology ,Quality of Life ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
AIMS Surgical ventricular reconstruction to remodel, reshape, and reduce ventricular volume is an effective therapy in selected patients with chronic heart failure (HF) of ischaemic aetiology. The BioVentrix Revivent TC System offers efficacy comparable to conventional surgical ventricular reconstruction and is less invasive utilizing micro-anchor pairs to exclude scarred myocardium on the beating heart. Here, we present 12-months follow-up data of an international multicenter study. METHODS AND RESULTS Patients were considered eligible for the procedure when they presented with symptomatic HF [New York Heart Association (NYHA) class ≥II], left ventricular (LV) dilatation and dysfunction caused by myocardial infarction, and akinetic and/or dyskinetic transmural scarred myocardium located in the anteroseptal, anterolateral, and/or apical regions. A total of 89 patients were enrolled and 86 patients were successfully treated (97%). At 12 months, a significant improvement in LV ejection fraction (29 ± 8% vs. 34 ± 9%, P
- Published
- 2019